The researchers also projected that newly diagnosed MM cases will increase by 70.8% by 2045 — from about 188,000 cases in 2022 to about 321,000 cases in 2045. The number of deaths due to MM is ...

Study finds low peripheral blood lymphocyte count at diagnosis predicts worse overall survival in multiple myeloma patients.

The publication of the pricing and reimbursement decision for Pepaxti (melflufen) in the Gazetta Ufficiale removes the last ...

Paris: Following the adoption of a positive opinion by the European Medicines Agency's (EMA) Committee for Medicinal Products ...

Bispecific antibodies have altered the multiple myeloma (MM) treatment landscape, but some practices still lack enough familiarity with these therapeutics to deliver them in outpatient settings.

Medically reviewed by Marla Anderson, MD Multiple myeloma is a rare blood cancer that develops in the plasma cells, which are ...

The company's multiple myeloma franchise, which includes Carvykti, stands to contribute significantly to its growth in 2025.

Recovery from multiple myeloma leads to a renewed sense of purpose and determination, with hope found in small victories. The ...

Sanofi’s Sarclisa has been approved by the European Union as the first anti-CD38 therapy in combination with VRd to treat adult patients with n ...

Infection risk remains a prominent clinical concern for patients with multiple myeloma (MM), even with the advent of modern, ...

Traditionally carrying a dire prognosis, the treatment paradigm for multiple myeloma is changing, with CAR T therapies, ...

Therapy will cost Rs 35 to 50 lakh. India sees around 1.20 lakh new blood cancer cases and over 70,000 deaths annually from ...